

27 DEC 2304

PA 1246621

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


November 10, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 10/702,044

FILING DATE: November 06, 2003

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN  
Certifying Officer

BEST AVAILABLE COPY



13281 U.S. PTO

Gary M. Nath (DC, NJ)  
 Todd L. Juneau (DC, NJ)  
 Ross A. Epstein (CA)  
 Marvin C. Berkowitz (CA)  
 Robert C. Ryan (NY, NJ)

Harold L. Novick (DC, NJ)

Irvin A. Lavine (CA), Retired  
 Donald M. Sandler (CA), Retired\*  
 Patent, Trademark and Copyright Causes  
 Unfair Competition, Trade Secrets,  
 Licensing and Litigation

+ + Of Counsel

# **NATH & ASSOCIATES PLLC**

Attorneys at Law  
 1030 Fifteenth Street, N.W.  
 Sixth Floor  
 Washington, D.C. 20005-1503

TELEPHONE (202) 775-8383  
 (202) 775-9393

FACSIMILE (202) 775-8396  
 (202) 822-9409

E-MAIL: IP@NATHLAW.COM  
 WEB: WWW.NATHLAW.COM

Michelle L. Hartland (VA)\*  
 Lee C. Heiman (CA)\*  
 Jerald L. Meyer (VA)\*  
 Tanya E. Harkins (MD)\*  
 Joshua B. Goldberg (VA)\*  
 Sheldon M. McGee (DC)  
 Derek Richmond (VA)\*  
 Alvin E. Tanenholtz\*\*  
 Angela Y. Dai\*\*

\*Practice limited to Matters and Proceedings  
 before Federal Courts and Agencies; not  
 Admitted in DC

\*\* Registered Patent Agent; not Admitted in DC

## **FORM PTO-1082**

### **TRANSMITTAL FOR NEW U.S. PATENT APPLICATION**

Commissioner of Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Re: New U.S. Patent Application  
 For: **METHOD AND SYSTEM FOR NON-INVASIVE DETERMINATION  
 OF BLOOD-RELATED PARAMETERS**

Inventor(s): Ilya FINE  
 Alexander FINAROV  
 Iosef GANDELMAN  
 Boris FIKHTE

Attorney Docket: 25815

Sir:  
 Attached hereto is the application identified above, including:

- 34 Pages Application Consisting of:
  - 23 Pages of Textual Specification
  - 6 Page of 36 Claims
  - 1 Abstract of the Disclosure
  - 4 Sheets of drawings.
- ☐ Preliminary Amendment
- ☐ Executed Inventor's Declaration
- ☒ Unexecuted Inventor's Declaration
- ☐ Assignment and cover sheet
- ☐ Priority Document
- ☐ Information Disclosure Statement

The Government filing fee\* is calculated as follows:

Total Claims . . . . .	36 - 20 = 16	x \$18.00 =	\$288.00
Independent Claims . . . . .	<u>2</u> - 3 = <u>0</u>	x \$84.00 =	\$0.00
Base Fee . . . . .			\$770.00
Multiple Dependent Claim Fee (\$290.00) . . . . .			\$ 0.00
Subtotal . . . . .			<u>\$1,058.00</u>

#### **TOTAL FILING FEE\***

(accounting for small entity status) . . . . . \$529.00


16334 U.S. PTO  
 10/702044



- ☒ Reduced by one-half, as applicant(s) is/are a "small entity".  
Applicant asserts eligibility for Small Entity Status.
- ☐ Benefit is claimed under 35 U.S.C. ' 119(e) from U.S.  
Provisional Patent Application(s) No. \_\_\_\_\_ filed  
\_\_\_\_\_.
- ☐ Foreign priority is claimed under 35 U.S.C. ' 120 from  
\_\_\_\_\_ Patent Application(s) No. \_\_\_\_\_ dated \_\_\_\_\_.
- ☐ Priority document(s) will be submitted at a later date.
- ☐ Priority document(s) is/are submitted herewith.
- ☒ Executed Declaration(s) will be submitted at a later date  
pursuant to 37 CFR ' 1.41 and ' 1.53, with an appropriate  
surcharge under 37 CFR ' 1.16(e).
- ☒ Formal drawing(s) is/are attached.
- ☐ Formal drawing(s) will be submitted at a later date.
- ☐ Assignment document(s) is/are submitted herewith; the recorda-  
tion fee of \$40.00 per document is enclosed herewith.
- ☒ Assignment document will be submitted at a later date.
- ☐ A Verified Translation will be submitted at a later date.
- ☒ No payment is enclosed at this time. Full payment will be  
made when the executed Declaration is submitted.
- ☐ Submitted herewith is a check in the amount of \$ \_\_\_\_\_.

Respectfully submitted,

NATH & ASSOCIATES PLLC



Gary M. Nath  
Registration No. 26,965  
Lee C. Heiman  
Registration No. 41,827  
Customer No. 20529

Date: November 6, 2003  
NATH & ASSOCIATES PLLC  
1030 15<sup>TH</sup> Street NW - 6<sup>TH</sup> Floor  
Washington, D.C. 20005  
(202)-775-8383  
GMN/LCH/dd (1082)

MAIL STOP PATENT APPLICATION  
Attorney Docket No. 25815

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

FINE et al.

Serial No. NOT YET ASSIGNED

Filed: November 6, 2003

For: METHOD AND SYSTEM FOR NON-INVASIVE DETERMINATION OF BLOOD-RELATED PARAMETERS

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) PTO Form-1082
- (3) 34 page Application consisting of:
  - 23 pages Textual Specification
  - 6 pages of 36 claims
  - 1 page containing the Abstract of the Disclosure
  - 4 sheets drawings;
- (4) Unexecuted Declaration/Power of Attorney
- (5) Postcard for early notification of serial number.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By:

  
Gary M. Nath  
Registration No. 26,965  
Lee C. Heiman  
Registration No. 41,827  
Customer No: 20529

Date: November 6, 2003  
NATH & ASSOCIATES PLLC  
1030<sup>th</sup> 15<sup>TH</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
GMN/LCH/dd:APPL.trans

## **Method and system for non-invasive determination of blood-related parameters**

### **FIELD OF THE INVENTION**

This invention relates to techniques for non-invasive measurements of blood-related parameters, and in particular, to methods and systems for measuring blood characteristics by photo-acoustic and electrical measurement techniques.

### **5 BACKGROUND OF THE INVENTION**

Non-invasive techniques for measuring various blood parameters, e.g. the concentration of glucose in blood, blood oxygen saturation, etc. have become very popular, since they do not require the withdrawal of a blood sample from a patient's body. One approach for non-invasively determining the composition of blood  
10 makes use of the interaction of electromagnetic radiation with the blood under examination. It is known that electromagnetic radiation having appropriate characteristics may interact with blood in two primary ways. As it passes through a fleshy medium, the radiation is scattered and a portion of it will be absorbed. Different chemical species of the blood scatter and absorb to different degrees at  
15 different wavelengths. The physical composition of the fleshy medium will also effect its interaction with the radiation.

A number of methods have been proposed that use optical radiation to probe a patient's body (e.g., a finger) with the goal of determining the concentration of a component of the material.

20 For example, optical monitoring techniques can utilize the detection of light transmitted or reflected from the location on the patient's body under measurement, and are based on spectrophotometric measurements enabling the indication of the

presence of various blood constituents based on known spectral behaviors of these constituents. Usually, the optical monitoring techniques utilize a measurement optical device or probe attached to the patient's finger, and include an optical assembly for irradiating the finger with light and detecting its light response. For  
5 example, the conventional device of the kind specified, such as a pulse oximeter, which is the generally accepted standard of everyday clinical practice, provides for measuring enhanced optical pulsatile signals caused by the changes in the volume of blood flowing through a finger.

It is known that for some blood parameters other than oxygen saturation,  
10 e.g., glucose concentration, significant difficulties have been encountered, because their absorption spectral behavior in red and near infrared regions is not as remarkable perceptible as for the oxygenized hemoglobin. Hence, the main limitations of the non-invasive optic techniques other than pulse oximetry are associated with the limited selectivity of the absorption based method.

15 Another optical technique is disclosed in U.S. Patent No. 6,400,972, International Applications WO 01/45553 and WO 01/96872, all assigned to the assignee of the present application. This is an occlusion-based technique, according to which over-systolic pressure is applied to the blood perfused fleshy medium with a normal blood flow so as to create a state of temporary blood flow cessation at the  
20 measurement location. The measurement with different wavelengths of incident radiation and/or different polarization states of detected light are carried out at sessions which are separate in time and taken during a cessation time period, i.e., when the state of blood flow cessation is maintained. This technique utilizes the condition of "artificial blood kinetics" rather than "natural blood kinetics" taking  
25 place when the state of total blood cessation is not achieved. As a result of the cessation of blood flow, a condition of artificial kinetics is achieved with the optical characteristics of the blood associated with the light response being different from those of natural blood kinetics. Indeed, it is known that the scattering properties of blood depend on the size and shape of scatterers (aggregates). Thus, time changes  
30 of the light response at the condition of artificial kinetics depend on the changes in

the shape and average size of the scattering centers in the medium, i.e., red blood cells (RBC) aggregation (Rouleaux effect). It was found that owing to the effect of artificial kinetics, the optical characteristics of blood changes dramatically, such that they differ from those of the fleshy medium with a normal blood flow by about 25 to 45%, and sometimes even by 60 %. Hence, the accuracy (i.e., signal-to-noise ratio) of the technique based on artificial kinetics, as well as selectivity of the optical measurements, can be substantially better when compared with those based on measurements of blood parameters at natural kinetics.

Fig. 1 illustrates an example showing a typical plot representing light transmission/absorption characteristic (light responses) of blood obtained over the time interval when the condition of artificial kinetics is created, maintained during a certain cessation time, and then released. In particular, the plot shows how the light-transmitting characteristic of blood changes under the application and release of the primary over-systolic pressure. The transmitting characteristics are shown in Fig. 1 in Transmission Arbitrary Units (T.A.U.).

The application of primary pressure to the fleshy medium starts at a moment  $T_{start}$  and is maintained for a period of time so as not to cause irreversible changes in the medium (e.g., 4 seconds). The pressure is released at the moment  $T_{release}$ . Measurements of the Relative Transmission are performed continuously, starting prior to the application of the over-systolic pressure. Different regions of light responses of the medium, designated A, B, C, D and E, corresponding to the different states of the blood flow are observed. Region A corresponds to a state of normal blood flow before the over-systolic pressure is applied. As shown, this region is characterized by a standard fluctuating value of the relative light transmission of blood. Region B starts at moment  $T_{start}$  (when the pressure is initially applied) and maintains over a short period of time  $T_B$  (about 0.5sec) following the actual start of the condition of artificial blood kinetics. Measurements taken over this time period are not steady and can be disregarded, due to the unavoidable influence of motional and/or other factors causing non-monotonic fluctuations of the light transmission. Region C corresponds to a state of the

temporary cessation of blood flow, which lasts within a cessation time  $T_C$  between a moment determined as  $(T_{start} + T_B)$  and the moment  $T_{release}$ . During this cessation time,  $T_C$ , the ascending curve (as shown in Fig. 1) or descending curve (not shown), depending on the incident wavelength of relative light transmission of blood, can be observed. It should be noted that this is the region where the condition of artificial kinetics is maintained over  $T_C$ . Generally, the light transmission curve can reach an asymptotic maximum over one second to several minutes. Region D corresponds to a transitional state of blood flow, which takes place after releasing the over-systolic pressure. This state starts with a slight delay  $T_d$  (approximately 0.5sec), i.e., at the moment determined as  $(T_{release} + T_d)$ . During the time period  $T_D$  of the duration of region D, the relative transmission of blood monotonously descends until it reaches values characteristic of the normal blood flow. Such a moment is marked as  $T_{end}$  in the drawing. Usually, the end of region D, and the beginning of region E, is detected when the changes of the light transmission become periodic and minimal (about 2%). Region E corresponds to a state of the normal blood flow, which is similar to that in region A.

It has also been shown in the prior art that photo-acoustic laser spectroscopy can be used for measuring glucose concentration in blood. In this technique, a laser beam is used to rapidly heat a sample generating an acoustic pressure wave produced in a sample, where the excitation beam is absorbed, that can be measured by high-sensitivity ultrasonic detectors such as piezo-electric crystals, microphones, optical fiber sensors, laser interferometers or diffraction sensors. Prior art techniques for non-invasive measurement of blood glucose by photo-acoustic spectroscopy are described, for example, in U.S. Pat. Nos. 5,348,002 to Caro; 5,941,821 to Chou; and 6,466,806 to Geva, *et. al.*

U.S. Pat. No. 5,348,002 to Caro discloses a technique for measuring blood glucose which includes a light source for applying electromagnetic radiation to patient's finger under analysis and a transducer for detecting acoustic energy. The transducer is positioned on one side of the finger and the incoming electromagnetic wave impinges on the other side of the finger, opposite the transducer.



The main disadvantage of this technique is that a tissue, such as a body part, is optically thick. The impinging electromagnetic energy is almost totally absorbed by the tissue. Consequently, the measured acoustic wave will respond to the total incident electromagnetic energy, rather than to the fraction absorbed by the glucose.

5        Moreover, it is well known that the water content in skin or blood can be more than 70%, making water the main absorbing substance. The effect of strong water absorption is twofold. First, because tissue has a high percentage of water, water absorption can prevent a light beam from penetrating a sufficient depth through tissue. Second, water absorption can yield an acoustic signal which is  
10        overwhelming compared to that of glucose. The technique disclosed in U.S. Pat. No. 5,348,002 fails to address the adverse effects caused by the absorption of radiation by water, rather than the medium to be measured, such as glucose.

Another photo-acoustic method for non-invasive monitoring of glucose is described in U.S. Pat. No. 5,941,821 to Chou, in which an excitation source  
15        provides electromagnetic energy at a wavelength corresponding to the absorption characteristics of the analysis. Upon irradiation, acoustic energy is generated in a relatively thin layer of the sample to be measured, characterized by a heat-diffusing length. The acoustic emission is detected with a differential microphone, one end of which is positioned in a measuring cell and the other end of which is positioned in a  
20        reference cell. A processor determines the concentration of the substance being measured based upon the detected acoustic signal. In order to determine the concentration of glucose in the bloodstream, the excitation source is preferably tuned to the absorption bands of glucose in spectral ranges from about 1520-1850 nm and about 2050-2340 nm to induce a strong photo-acoustic emission. In these  
25        wavelength ranges, water absorption is relatively weak and glucose absorption is relatively strong. Thus, even though a tissue may have a high percentage of water at the above-specified wavelength ranges, the electromagnetic radiation is able to penetrate through the tissue to a sufficient depth to allow for measurements.

U.S. Pat. No. 6,466,806 to Geva, *et. al* describes a method and apparatus of  
30        resonant photo-acoustic spectroscopy (RPAS) for determining a concentration of an

interest component in a medium. The method comprises irradiating a surface of the medium with a light pulse-train comprising equidistant short pulses having variable duration, frequency, number, and power. The frequency of the light short pulses is chosen equal to a natural acoustic oscillation frequency in a medium for resonant  
5 light-excitation of acoustic modes. The wavelength of the light pulses is selected so as to excite resonant acoustic oscillation in the medium due to the absorption of light by the interest component and subsequent adiabatic temperature rise in the testing area of the medium.

Some of the non-invasive methods of determining the concentration of the  
10 chemical of interest (e.g., glucose) in blood are based on measuring impedance (total electrical resistance) or a component of the impedance of a body part of a patient. For example, U.S. Pat. No. 5,792,668 to Fuller, *et al.*, describes a technique in which two electrodes are brought into direct contact with the human body and real and imaginary components of reflected and/or transmitted electromagnetic  
15 signals are spectrally examined as a function of frequency to identify the concentration of the chemical of interest. The examination can include the analysis of the effective complex impedance presented by the human body, and/or the effective phase shift between the transmitted and reflected signal at the human body.

20 It is known that the total electrical impedance of a human body, as well as the components of the total electrical impedance, depend not only on the actual value of the concentration of glucose in blood, but also on the temporal rate of change of that concentration. The rate of change of the glucose concentration is specific to each individual and varies within certain limits depending on a number  
25 of reasons and factors, such as, for example, environmental, psycho-physiological, nutritional, specific metabolic factors and others.

International Publication No. WO02069791 to Schrepfer, *et al.* discloses a technique for determining the concentration of a substance in body liquid. In one of the embodiments, WO02069791 describes a device suited for in-vivo  
30 measurements of the human body. The device comprises an elongate electrode

having a width much smaller than its length. A holder is provided to mount the electrode to an arm or a leg with the longitudinal axis of the electrode extending parallel thereto. In this way, a large interaction space is established, which allows to measure the desired concentration with a higher level of accuracy. The method of  
5 determining the glucose concentration comprises the steps of arranging a first electrode, which is electrically insulated from the specimen, applying a modulated electrical voltage having a frequency between 10 MHz and 2 GHz to the first electrode for generating a modulated field in the specimen and measuring parameters that depend on the electrical impedance of the specimen.

10 U.S. Patent Application Publication No. 2002/0155615A1 to Novikov, *et. al.* describes a method of non-invasive determination of a glucose concentration in blood based on the measurements of the total impedance of the skin of a patient taking into account the rate of change of the glucose concentration. The method is based on a linear model of a first order correlation between the glucose  
15 concentration and the total impedance. The determination of the concentration of glucose  $G(t)$  in blood comprises measuring the total impedance  $N(x)$  or a component of the total impedance of the skin, and then determining the concentration of glucose in accordance with the following approximating equation:

$$G(t) = G_1 \exp(-a_0 t) + q + a_1 \exp(-a_0 t) \int_0^t N(x) \exp(a_0 x) dx,$$

20 where  $G_1 = G_0 - q$ ;

$G_0$  is the initial concentration of glucose in blood at the beginning of the measurement process,  $q$  is a parameter that characterizes the ability of a human organism to maintain homeostasis relative to the glucose concentration in blood,  $a_0$  is a coefficient that characterizes the correlation between a total electrical  
25 impedance (or its components) of the skin and a concentration of glucose in blood of a specific individual, and  $a_1$  is a coefficient taking into account the variability of the external factors and specific characteristics of an individual. The coefficients  $q$ ,  $a_0$  and  $a_1$  used in an approximating function are determined at the preliminary stage measurements by an invasive method.

## SUMMARY OF THE INVENTION

Despite their potential, the known photo-acoustic and impedance methods suffer from limited accuracy. The present invention facilitates non-invasive measurement of blood parameters by providing a novel method and device for  
5 measuring time variations of a response of the blood perfused fleshy medium (e.g., finger) to an external electromagnetic field. According to one embodiment, the response to the external electromagnetic field is a photo-acoustic signal obtained in response to the exciting light. According to another embodiment, the response to the external field is the impedance of the medium in response to the applied *ac*  
10 electromagnetic field.

It should be noted that in the present description, the term "impedance" hereinafter will, for brevity, include not only total electrical resistance, but also each component of the impedance. The measured components of the impedance of the medium can, for example, be as follows: an active component, a reactive  
15 component, a phase angle between the active and reactive components of the impedance, as well as parameters that can be derived from the impedance and its components. These parameters include, *inter alia*, dielectric permittivity, dielectric losses and conductivity of the medium.

For both techniques (photo-acoustic and impedance measurements), the  
20 invention utilizes the benefits of occlusion-based measurements described above in connection with optical measurement techniques. Namely, the measurement of time variations of the response of the blood perfused fleshy medium by occlusion-based techniques is based on creating and controlling the artificial blood kinetics in the medium. The condition of artificial kinetics is created and maintained for a certain  
25 time period by applying primary over-systolic pressure to a certain location at the medium with a normal blood flow so as to achieve a state of temporary blood flow cessation at the medium downstream of the certain location. When required, the control of the condition of the artificial kinetics can be further achieved by applying a perturbation of a secondary pressure to the fleshy medium.

There is thus provided according to one broad aspect of the invention a non-invasive method for use in determination of at least one desired characteristic of blood of a patient, the method comprising:

- 5 (a) creating a condition of artificial blood kinetics at a measurement location in a patient's blood perfused fleshy medium and maintaining this condition for a certain time period;
- (b) applying an external electromagnetic field to the measurement location;
- (c) detecting a time response of the medium from at least a portion of the measurement location to said external electromagnetic field; and
- 10 (d) generating measured data indicative of time evolutions of the response of the medium over at least a part of said certain time period;

wherein the response to said external electromagnetic field includes at least one of the following:

15 an acoustic response to illuminating incident light having a wavelength in a range where the scattering properties of blood are sensitive to light radiation, and

an impedance of the portion of the medium.

The method further comprising:

- 20 (e) analyzing said measured data for determining at least one characteristic parameter derived from said time response of the medium;
- (f) providing predetermined reference data sensitive to patient individuality and indicative of the desired blood characteristic obtained by another independent method as a function of said characteristic parameter; and
- (g) utilizing the determined characteristic parameter derived from said time response of the medium and said predetermined reference data for obtaining
- 25 a value of the desired blood characteristic.

According to another broad aspect of the invention there is provided a system for non-invasive determination of at least one desired characteristic of blood of a patient, the system comprising:

(i) a pressurizing assembly arranged for creating a condition of artificial blood kinetics at a measurement location in a patient's blood perfused fleshy medium and at least maintaining this condition for a certain time period;

(ii) a measuring probe including

5           a source of an external electromagnetic field configured for applying said external electromagnetic field to said measurement location, and

          a detecting module configured for detecting a time response of the medium from at least a portion of the measurement location to said  
10       external electromagnetic field; and

(iii) a control unit electrically coupled to said pressurizing assembly, said control unit including:

          a memory for storing reference data sensitive to patient individuality and indicative of the desired blood characteristic as a function  
15       of a characteristic parameter derived from said time response; and

          a data acquisition and processing utility coupled to the detecting module for receiving and analyzing measured data therefrom and configured to utilize the reference data and determine said at least one desired blood characteristic.

20       The pressurizing assembly includes a primary occlusion cuff for applying primary over-systolic pressure to the fleshy medium at a primary pressure location. When required, the pressurizing assembly can include a secondary occlusion cuff for applying secondary pressure to the fleshy medium at a secondary pressure location, thereby altering the condition of the artificial blood kinetics at the  
25       secondary pressure location over a predetermined time interval within said certain time period, so as to modulate properties of the blood affecting the time response.

          The primary pressure location can be selected upstream of the secondary pressure location with respect to the normal blood flow direction in the medium. The secondary pressure location can be in the vicinity of the measurement location.

According to one embodiment, the measuring probe can be a photo-acoustic system, where the source of the external electromagnetic field can be configured for generating a light beam in the wavelength range where the scattering or absorbing properties of the patients blood are sensitive to provide an acoustic  
5 response, and the detecting module is an acoustic detector. According to another embodiment, the measuring probe can be a system for measuring impedance of at least a portion of the medium at the measurement location.

According to one embodiment, the reference data can be a calibration curve defining a dependence of the characteristic parameter on the desired blood  
10 characteristic. The characteristic parameter can, for example, be an actual value of the time response at a certain moment during said certain time period. The certain moment can be chosen when the response attains its near asymptotic magnitude.

According to another embodiment, the characteristic parameter can be a parametric slope defined as a ratio between a first function depending on a time  
15 response of the medium corresponding to a first frequency of the external electromagnetic field and a second function depending on the time response of the medium corresponding to a second frequency. According to one example, the first and second functions can be logarithmic functions of the response corresponding to the first and second frequencies, respectively. According to another example, the  
20 first and second functions can be a time rate of the changes of the response corresponding to the first and second frequencies, respectively.

There has thus been outlined, rather broadly, the more important features of the invention in order that the detailed description thereof that follows hereinafter may be better understood. Additional details and advantages of the invention will  
25 be set forth in the detailed description, and in part will be appreciated from the description, or may be learned by practice of the invention.

## BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

5        **Fig. 1** illustrates a typical plot representing light transmission characteristics of blood obtained when the condition of artificial kinetics is created and changed;

**Fig. 2** illustrates an example of the computer simulation of the scattering coefficient of the blood *versus* the light absorption changes during the condition of the artificial kinetics;

10       **Fig. 3** illustrates time behavior of light absorption in the above computer simulation caused by the artificial blood kinetics;

**Fig. 4** illustrates time dependence of a typical PA signal (normalized value) obtainable during the condition of artificial blood kinetics;

**Fig. 5** illustrates an example of a time dependence of a typical impedance  
15 signal obtainable during the condition of artificial blood kinetics; and

**Fig. 6** illustrates a schematic block diagram of a measuring system for carrying out the method of the present invention, according to one embodiment of the invention.

## 20 DETAILED DESCRIPTION OF THE INVENTION

The principles and operation of the system and method for non-invasive measurement of blood parameters according to the present invention may be better understood with reference to the drawings and the accompanying description, it being understood that these drawings and examples in the description are given for  
25 illustrative purposes only and are not meant to be limiting. The same reference Roman numerals and alphabetic characters will be utilized for identifying those components which are common in the system for non-invasive measurement of blood parameters shown in the drawings throughout the present description of the invention.



According to one general aspect, the present invention provides a novel method for non-invasive electromagnetic scattering determination of glucose. It should be understood that the present invention is not limited to the measurement of blood glucose levels, but may also be utilized to measure other blood characteristics. Examples of the blood characteristics include, but are not limited to the concentration of a substance in patient's blood (e.g., glucose, hemoglobin), oxygen saturation, Erythrocyte Sedimentation Rate (ESR) and Erythrocyte Aggregation Rate (EAR).

The method is based on creating and, when required, controlling the artificial blood kinetics in a patient's blood perfused fleshy medium, e.g., his finger, and applying photo-acoustic and impedance measurements thereto. The condition of artificial kinetics is created and maintained for a certain time period. The creation of the condition of artificial kinetics is preferably made by applying a primary over-systolic pressure to a certain location at the medium with a normal blood flow so as to achieve a state of temporary blood flow cessation, as described above in the background section.

According to the invention, when required, control of the condition of the artificial kinetics can be carried out by applying a perturbation of a secondary pressure to the fleshy medium, as will be described in detail hereinbelow.

According to one embodiment of the invention, the controllable altering of the condition of the artificial blood kinetics is performed by applying a perturbation to the medium by a secondary pressure pulse of a predetermined value over the predetermined time interval so as to modulate scattering/absorbing properties of blood. According to one example, the secondary pressure can be applied to the medium (e.g., patient's finger) at the location of the main occlusion providing the over-systolic pressure. According to another example, the secondary pressure can be applied to the medium at a certain location selected downstream of the main occlusion with respect to the blood flow direction. It should be noted that the location of the application of the secondary pressure may either coincide with the location of a response signal detector or slightly differ from it, depending on the

kind of measured medium and/or design of the measurement probe. The physical effect of the secondary pressure results, *inter alia*, in the modification of the aggregates of red blood cells (RBC). Therefore, the location of the application of the secondary pressure has to be in the vicinity of the measurement place.

5       The altering of the condition of artificial blood kinetics includes applying a perturbation to the medium by at least one secondary pressure pulse of a predetermined value over a certain time period which is insufficient for irreversible changes in the fleshy medium. The predetermined value of the secondary pressure pulse can, for example, be in the range of about 0-300 mmHg. It was also found by  
10   the inventors that one can obtain some more useful information about the patient's blood characteristics by means of manipulating the magnitude of the secondary pressure pulse. In particular, in the case when the magnitude of the secondary pressure pulse is small and does not exceed a certain relatively small value  $P_1$ , all three main components of the blood (venous, capillary and arterial blood  
15   components) can contribute to the measurements. However, in the case when the magnitude of the secondary pressure exceeds the value of  $P_1$  the venous blood component can be excluded from the consideration. Likewise, in order to exclude from the consideration also the capillary blood component, the secondary pressure should exceed the value of  $P_2$  (where  $P_2 > P_1$ ). In other words, when the magnitude  
20   of the secondary pressure is over  $P_2$  venous and capillary blood becomes forced out of the measurement location, while arterial blood remains at the measurement location, and measurements in this case would be applied to arterial blood only. It should be understood that the values of  $P_1$  and  $P_2$ , depend on the person's physiology, and should be selected individually for each patient.

25       A modification of RBC clusters resulting in the altering of the artificial kinetics can be caused by many different ways. Thus, other than the single secondary pulse described above, the altering of the condition of artificial blood kinetics can be carried out by applying a perturbation to the medium by means of the secondary pressure of a predetermined cyclic pattern over the predetermined  
30   time interval. The predetermined cyclic pattern can, for example, be in the form of a

train of short secondary pressure pulses having a duration of about 0.5-2 seconds and amplitude in the range of about 0-300 mmHg.

According to one embodiment of the invention, the non-invasive measurements are carried out by illuminating a measurement location on the medium at the state of temporary blood flow cessation with an incident light beam, and detecting acoustic energy as a response to the incident electromagnetic energy (light in this case). The light beam is usually a pulsed laser signal having the wavelength selected from a range where the scattering or absorbing properties of blood are sensitive to provide an acoustic response (e.g., 1500-1700nm).

According to Beer's law, the optical absorption coefficient, and consequently the corresponding photo-acoustic signal, are proportional to the concentration of the component of interest in the medium being tested. Moreover, changes of the absorption/scattering properties of the blood due to the altering of the artificial kinetics will also be reflected on the corresponding photo-acoustic response.

Fig. 2 illustrates an example of the computer simulation of the light absorption changes *versus* the scattering coefficient of the blood, when the condition of the artificial kinetics changes over time, for example, due to the cessation of blood flow (caused by the described above occlusion maneuver). The computer simulations were carried out for a blood layer of 1 mm thickness, with Hematocrit 0.4 and a light wavelength of 900nm. It was assumed that at the beginning of the aggregation process, the red blood cells (RBC) were all in a non-aggregated state (e.g., individual red blood cells) that corresponds in this example to the scattering coefficient of single red blood cells, viz.  $100 \text{ mm}^{-1}$ . As can be seen, the changes of the artificial blood kinetics results in the increase of absorption, due to the prolongation of the optical path.

Fig. 3 illustrates the time behavior of light absorption in the above computer simulation caused by changes in the artificial blood kinetics. As can be appreciated, the prolongation of the optical path, owing to the RBC aggregation, consequently, causes the reduction of light absorption.

In turn, a photo-acoustic response is proportional to the light absorption and the scattering coefficient of blood. Fig. 4 illustrates a time dependence of a typical PA signal (normalized value) obtainable during the condition of artificial blood kinetics (i.e., RBC aggregation process). The wavelength of the illumination light  
5 for this simulation corresponds to 900nm

It should be appreciated that a curve of the corresponding time dependence can also be obtained for a photo-acoustic signal when the condition of the artificial blood kinetics is controllably altered by applying a perturbation to the flesh medium by a predetermined secondary pulse, as described above. In particular, the measured  
10 data of the photo-acoustic signal over a certain time interval selected from the intervals when the secondary pressure is applied can be used. Moreover, the measured data over a certain interval selected from the time intervals after the release of the secondary pressure can also be utilized for determining blood characteristics.

15 According to another embodiment of the invention, the response to the external electromagnetic field is the impedance of the medium in response to the applied *ac* electromagnetic field. For example, the basic principles of Time Reflection Spectroscopy or Time Domain Dielectric Spectroscopy (see, for example, Yu. Feldman etc., "Time Domain Dielectric Spectroscopy: An Advanced  
20 Measuring System." *Rev. Sci. Instrum.*, 1996, V. 67, (9), P. 3208-3216) can be used for determination of the impedance.

It should be noted that components of the impedance or parameters that can be derived from the impedance or its components also can be utilized as a response to the external electromagnetic field. The measured components of the impedance  
25 of the medium can be the following: an active component, a reactive component, or a phase angle between the active and reactive components of the impedance. These components allow to derive, *inter alia*, such parameters as dielectric permittivity, dielectric losses and conductivity of the medium.

It is well known that dielectric properties of RBC depend on the glucose  
30 concentration. In particular, it was measured that impedance of the blood can

increase by 0.25 ohm when the glucose level increases by 10 mg/dl. Since this effect is mainly related to the cellular membranes, then the change of the RBC's membranes surface during the aggregation caused by the artificial kinetics should lead to a change in the measured impedance signal. It can be assumed that the  
5 impedance signal is proportional to the free surface of RBCs. Thus, the aggregation of  $N$  RBCs will approximately reduce the free surface by factor  $(N+r/h)/(1+r/h)$ , where  $r$  and  $h$  are the radius of the RBC and the RBC's membrane thickness, respectively. In calculations,  $r$  and  $h$  can, for example, be set to 4 micron and 1 micron, respectively. Accordingly, the measured entire blood impedance should be  
10 varied due to the aggregation process. An example of a dependence of a typical impedance signal versus Number of RBC in an aggregate obtainable during the condition of artificial blood kinetics (i.e., RBC aggregation process) is shown in Fig. 5:

The rate of change of the impedance during the state of the artificial kinetics  
15 is specific to each individual and can be used for obtaining the corresponding glucose concentration. Hence, the accuracy (i.e., signal-to-noise ratio) of the technique based on the artificial kinetics can be substantially better when compared to those based on measurements of the blood parameters at natural kinetics.

Moreover, when required to further increase the sensitivity, the altering  
20 component of the impedance (associated with the aggregation) can be easily extracted from the total blood impedance that includes also the components of impedance which are insensitive to the aggregation process, e.g., the components related to skin, water, swear, *etc.*

It should be appreciated that a certain curve of the corresponding time  
25 dependence can also be obtained for impedance when the condition of the artificial blood kinetics is controllably altered by applying a perturbation to the flesh medium by a predetermined secondary pulse, as described above. In particular, for determining blood characteristics the entire impedance or its component (measured data) can be used measured over a certain interval selected from the intervals when  
30 the secondary pressure perturbations are applied. Moreover, the measured data over

a certain interval selected from the time intervals after the release of the secondary pressure perturbations can also be utilized.

According to the invention, for the determination of blood characteristics, a characteristic parameter should be used derived from the time variations of the response (photo-acoustic signal and/or impedance) of the medium during either the condition of the artificial blood kinetics or when this condition is altered by the secondary pressure perturbations. Since the determination of this parameter does not depend on the details of the employed technique and is similar for the response obtained from either photo-acoustic or impedance measurement techniques, the examples of the procedures for determination of blood characteristics (e.g., glucose concentration) will be shown herebelow for the response corresponding to the generalized case.

According to one example, this characteristic parameter can be the actual value of the time response of the medium to an external electromagnetic field at a certain moment in time during the state of the artificial kinetics. For example, this time moment can be chosen when the response attains its asymptotic or almost asymptotic magnitude of the time response, e.g., at the moment of 1 minute after applying the external electromagnetic field. For instance, for the photo-acoustic measurements, the external electromagnetic field can be light, having the wavelengths selected from the range of 500-1700nm; while for the impedance measurements, the external electromagnetic field can be *ac* electromagnetic field having the frequency selected from the range of 1-200 MHz.

According to another example, this characteristic parameter can be a parametric slope (PS) defined as the ratio between a first function depending on a response of the medium corresponding to one wavelength (frequency) of the external electromagnetic field and a second function depending on the response of the medium corresponding to another wavelength (frequency). For instance, one of the wavelengths (frequencies) can always be selected in the glucose sensitive range, e.g. between 700-780nm for the photo-acoustic measurements, and 1-200MHz for

impedance measurements; while the other wavelength (frequency) can be taken either from the glucose sensitive range or outside of this range.

According to one embodiment, the first and second functions can be logarithmic functions  $\log(T_1)$  and  $\log(T_2)$  of the responses  $T_1$  and  $T_2$ , corresponding  
5 to the two different wavelengths (frequencies). According to another embodiment, the first and second functions can be functions of the time rate of the changes of the light response signal, i.e.,  $\Delta T/\Delta t$  (or  $\Delta \log T/\Delta t$ ), where  $\Delta t$  can be any part of the time interval during which the condition of artificial kinetics is maintained or altered.

It should be appreciated that the characteristic parameter utilized for  
10 calculation of the blood characteristics can be calculated as a function of various parameters obtained from more than one technique. For example, the characteristic parameter can be calculated as a predetermined relationship between the parameters obtained from photo-acoustic measurements in combination with impedance measurements.

15 According to the invention, for determining a desired blood characteristic, certain reference data sensitive to patient individuality should be provided. The reference data should be indicative of the desired blood characteristic (e.g., glucose concentration) as a function of the characteristic parameter derived as described above. Such reference data can, for example, be a calibration curve defining the  
20 dependence of the characteristic parameter on the desired blood characteristic. The calibration curve can be created by plotting a dependence of the characteristic parameter versus the desired blood characteristic that can be obtained for the particular individual or various patients by any other known invasive or non-invasive method which is independent of the current measurements. It should be  
25 appreciated that for different blood characteristics such independent methods may also be different. For example, a calibration curve to be used for determining the glucose concentration may be constructed by measuring the concentration of glucose in the blood by an invasive method simultaneously with the method of the present invention. Such measurements for constructing the calibration curve can be  
30 carried out either for a specific patient during a certain time period, sufficient to

observe changes of the concentration of his glucose, or by applying measurements to various patients having different glucose concentration. It should be appreciated that when required (e.g., for increasing accuracy of the measurement), a combination of several techniques can be used for obtaining a calibration curve.

5 Referring to Fig. 6, a schematic block diagram of a measuring system 60 applied to a patient's finger F for carrying out the method of the present invention is illustrated. It should be noted that the blocks in Fig. 6 are intended as functional entities only, such that the functional relationships between the entities are shown, rather than any physical connections and/or physical relationships. Although the  
10 application of the measuring system to the patient's finger F will be illustrated below, it should be understood that other parts of the patient's body, e.g., a toe, a wrist, an elbow and/or a knee, can also be used, *mutatis mutandis*, as a medium for the light transmission measurements. The system 60 comprises such main constructional parts as a measuring probe 61, a pressurizing assembly 62  
15 (occluder), and a control unit 63. The measuring probe 61 includes a source 611 of an external electromagnetic field configured for applying the field to the blood perfused fleshy medium (i.e., finger F), and a detecting module 612 configured for measuring the response of the medium to the external field.

According to one embodiment of the invention, the measuring probe 61 can  
20 be a photo-acoustic system that may be any known photo-acoustic system configured for irradiating the medium and detecting the generated acoustic energy. According to another embodiment of the invention, the measuring probe 61 can be any conventional system for measuring impedance of the medium and/or components of the impedance. According to a further embodiment of the invention,  
25 the measuring probe 61 includes a combination of a photo-acoustic system and a system for measuring impedance of the medium. According to yet a further embodiment of the invention, the measuring probe 61 includes a combination of a photo-acoustic system, a system for measuring impedance of the medium and any other system. An example of another system includes, but is not limited to, a photo-  
30 optical system described in U.S. Patent No. 6,400,972, International Applications



WO 01/45553 and WO 01/96872, all assigned to the assignee of the present application.

Numerous examples of the photo-acoustic and impedance measuring systems are well known in the art (see, for example, EP 0 282 234; U.S. Pat. Nos. 5 6,466,806; 6,049,728; 5,792,668; WO 00/43759; WO 02/069791), and therefore the detail of these systems will not be expounded herein below.

The pressurizing assembly 62 includes a primary occlusion cuff 621 operable for applying the primary over-systolic pressure to the patient's finger F at a location  $L_1$  and, when required, a secondary occlusion cuff 622 operable for  
10 applying the secondary pressure to the patient's finger at a location  $L_2$  in the vicinity of a measurement location ML. The pressurizing assembly 62 further includes a pressure driver 623 actuated by the control unit 64 for operating the squeezing of the cuff 621 and, when required, the cuff 622. The primary occlusion cuff 621 and the secondary occlusion cuff 622 may be of any known suitable type.  
15 It should be noted that the primary occlusion cuff 621 may, for example, be accommodated on the patient's wrist or palm, while the secondary occlusion cuff 622 and the detecting module 612 of the probe 61 (measuring either an acoustic response or impedance of the medium) may be located on the patient's finger.

Preferably, the location  $L_2$  is selected downstream of the main occlusion  
20 (location  $L_1$ ) with respect to the normal blood flow direction. Generally speaking, the locations to which the pressure and measurements are applied should preferably be aligned along the direction of the normal blood flow. It should be also noted that the measurement location ML may, for example, be accommodated so as to coincide with the location of applying the secondary pressure or slightly differ from  
25 it, depending on the kind of measured medium and/or design of the measuring probe 61.

A signal detected by the measuring probe 61 is fed to the control unit 63 through a suitable electronic interface block, typically including an analog-to-digital (A/D) converter (not shown) configured for generating measured data  
30 indicative of time evolutions of the response of the medium. The control unit 63 is

interconnected between the measuring probe 61 and the pressurizing assembly 62 for synchronizing the operation of the source 611 of the external field and the pressure driver 623 so as to apply primary over-systolic pressure to a certain location on the medium for creating a condition of artificial blood kinetics in the medium at the measurement location and maintaining this condition for a certain time period. Likewise, when required, the control unit 63 can provide synchronization for applying secondary pressure to the fleshy medium in the vicinity of or at the measurement location so as to alter the condition of artificial blood kinetics over a predetermined time interval within the certain time period, and thereby modulating the properties of blood affecting the time response. The control unit 63 is coupled to the output of the detecting module 612 for applying the measurements synchronously while maintaining and/or altering the condition of the artificial blood kinetics.

The control unit 63 includes a computer device having such known utilities as a memory 631 for storing, *inter alia*, reference data sensitive to patient individuality and indicative of the desired blood characteristic(s) as a function of a characteristic parameter derived, as have been described above, from the response of the medium. The control unit 63 further includes a processor 632 (data acquisition and processing utility), and a monitor 633 configured for presenting the measurement results. The processor 632 is preprogrammed by a suitable software model capable of analyzing the received output of the detecting module 612 (measured data) and determining one or more desired characteristics of the patient's blood by utilizing the reference data, as have been described above.

Those skilled in the art to which the present invention pertains, can appreciate that while the present invention has been described in terms of preferred embodiments, the concept upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, systems and processes for carrying out the several purposes of the present invention.

Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.

In the method claims that follow, alphabetic characters numerals used to  
5 designate claim steps are provided for convenience only and do not imply any particular order of performing the steps.

Finally, it should be noted that the word "comprising" as used throughout the appended claims is to be interpreted to mean "including but not limited to".

It is important, therefore, that the scope of the invention is not construed as  
10 being limited by the illustrative embodiments set forth herein. Other variations are possible within the scope of the present invention as defined in the appended claims and their equivalents.

**CLAIMS:**

1. A non-invasive method for use in determining at least one desired characteristic of blood of a patient, the method comprising:

- 5 (a) creating a condition of artificial blood kinetics at a measurement location in a patient's blood perfused fleshy medium and maintaining this condition for a certain time period;
- (b) applying an external electromagnetic field to the measurement location;
- (c) detecting a time response of the medium from at least a portion of the measurement location to said external electromagnetic field; and
- 10 (d) generating measured data indicative of time evolutions of the response of the medium over at least a part of said certain time period;

wherein the response to said external electromagnetic field includes at least one of the following:

- 15 an acoustic response to illuminating incident light having a wavelength in a range where the scattering properties of blood are sensitive to light radiation, and

an impedance of the portion of the medium.

2. The method of claim 1 further comprising:

- 20 (e) analyzing said measured data for determining at least one characteristic parameter derived from said time response of the medium;
- (f) providing predetermined reference data sensitive to patient individuality and indicative of the desired blood characteristic obtained by other independent method as a function of said characteristic parameter; and
- (g) utilizing the determined characteristic parameter derived from said time response of the medium and said predetermined reference data for obtaining
- 25 a value of the desired blood characteristic.

3. The method of claim 1 further comprising:

altering said condition of the artificial blood kinetics at the measurement location over a predetermined time interval within said certain time period so as to modulate properties of the blood affecting said time response.

4. The method of claim 3 further comprising:

5 analyzing said measured data for determining at least one characteristic parameter derived from said response of the medium;

providing predetermined reference data sensitive to patient individuality and indicative of the desired blood characteristic obtained by another independent method as a function of said characteristic parameter; and

10 utilizing the determined characteristic parameter derived from said response of the medium and said predetermined reference data for obtaining a value of the desired blood characteristic.

5. The method of claim 2 wherein said reference data is a calibration curve defining a dependence of the characteristic parameter on the desired blood  
15 characteristic.

6. The method of claim 4 wherein said reference data is a calibration curve defining a dependence of the parameter on the desired blood characteristic.

7. The method of claim 2 wherein said at least one characteristic parameter is an actual value of the time response at a certain moment during said certain time  
20 period.

8. The method of claim 7 wherein said certain moment is chosen when the response attains its near asymptotic magnitude.

9. The method of claim 4 wherein said at least one characteristic parameter is an actual value of the time response at a certain moment during said certain time  
25 period.

10. The method of claim 9 wherein said certain moment is chosen when the response attains its near asymptotic magnitude.

11. The method of claim 2 wherein said characteristic parameter is a parametric slope defined as a ratio between a first function depending on a time  
30 response of the medium corresponding to a first frequency of the external

electromagnetic field and a second function depending on the time response of the medium corresponding to a second frequency.

12. The method of claim 4 wherein this characteristic parameter is a parametric slope defined as a ratio between a first function depending on a time  
5 response of the medium corresponding to a first frequency of the external electromagnetic field and a second function depending on the time response of the medium corresponding to a second frequency.

13. The method of claim 11 wherein said first and second functions are logarithmic functions of the response corresponding to the first and second  
10 frequencies, respectively.

14. The method of claim 12 wherein said first and second functions are logarithmic functions of the response corresponding to the first and second frequencies, respectively.

15. The method of claim 11 wherein said first and second functions are a time  
15 rate of the changes of the response corresponding to the first and second frequencies, respectively.

16. The method of claim 12 wherein said first and second functions are a time rate of the changes of the response corresponding to the first and second frequencies, respectively.

20 17. The method of claim 1 wherein said creating of the condition of artificial kinetics includes applying primary over-systolic pressure to a certain location at the medium with a normal blood flow upstream of the measurement location so as to achieve a state of temporary blood flow cessation in the medium at the measurement location.

25 18. The method of claim 1 wherein said certain time period is insufficient for irreversible changes in the fleshy medium.

19. The method of claim 3 wherein said altering of the condition of artificial blood kinetics includes applying a perturbation to the medium by at least one secondary pressure pulse of a predetermined value over said predetermined time  
30 interval.

20. The method of claim 19 wherein the predetermined value of the secondary pressure is in the range of about 0-300 mmHg.

21. The method of claim 3 wherein said altering of the condition of artificial blood kinetics includes applying a perturbation to the medium by secondary  
5 pressure of a predetermined cyclic pattern over said predetermined time interval.

22. The method of claim 21 wherein said predetermined cyclic pattern is in the form of secondary pressure pulses having amplitudes in the range of about 0-300 mmHg.

23. The method of claim 1 wherein said at least one desired characteristic of  
10 the patient's blood is a concentration of glucose therein.

24. A system for non-invasive determination of at least one desired characteristic of blood of a patient, the system comprising:

(i) a pressurizing assembly arranged for creating a condition of artificial blood kinetics at a measurement location in a patient's blood perfused fleshy  
15 medium and at least maintaining this condition for a certain time period;

(ii) a measuring probe including

a source of an external electromagnetic field configured for applying said external electromagnetic field to said measurement location, and

20 a detecting module configured for detecting a time response of the medium from at least a portion of the measurement location to said external electromagnetic field; and

(iii) a control unit electrically coupled to said pressurizing assembly, said control unit including:

25 a memory for storing reference data sensitive to patient individuality and indicative of the desired blood characteristic as a function of a characteristic parameter derived from said time response; and

a data acquisition and processing utility coupled to the detecting module for receiving and analyzing measured data therefrom and

configured to utilize the reference data and determine said at least one desired blood characteristic.

25. The system of claim 24 wherein said pressurizing assembly includes a primary occlusion cuff for applying a primary over-systolic pressure to the fleshy  
5 medium at a primary pressure location.

26. The system of claim 25 wherein said pressurizing assembly further includes a secondary occlusion cuff for applying a secondary pressure to the flesh medium at a secondary pressure location, thereby altering said condition of the artificial blood kinetics at said secondary pressure location over a predetermined  
10 time interval within said certain time period so as to modulate properties of the blood affecting said time response.

27. The system of claim 26 wherein said primary pressure location is selected upstream of the secondary pressure location with respect to the normal blood flow direction in the medium, said secondary pressure location being in the vicinity of  
15 the measurement location.

28. The system of claim 24 wherein said measuring probe includes a photo-acoustic system, where said source of the external electromagnetic field being configured for generating a light beam in the wavelength range where the scattering or absorbing properties of the patients blood are sensitive to provide an acoustic  
20 response, and where said detecting module is an acoustic detector.

29. The system of claim 24 wherein said measuring probe includes a system for measuring impedance of at least a portion of the medium at the measurement location.

30. The system of claim 24 wherein said reference data is a calibration curve  
25 defining a dependence of the characteristic parameter on the desired blood characteristic.

31. The system of claim 30 wherein said at least one characteristic parameter is an actual value of the time response at a certain moment during said certain time period.



32. The system of claim 31 wherein said certain moment is chosen when the response attains its near asymptotic magnitude.

33. The system of claim 24 wherein said characteristic parameter is a parametric slope defined as a ratio between a first function depending on a time  
5 response of the medium corresponding to a first frequency of the external electromagnetic field and a second function depending on the time response of the medium corresponding to a second frequency.

34. The system of claim 33 wherein said first and second functions are logarithmic functions of the response corresponding to the first and second  
10 frequencies, respectively.

35. The system of claim 33 wherein said first and second functions are a time rate of the changes of the response corresponding to the first and second frequencies, respectively.

36. The system of claim 24 wherein said at least one desired characteristic of  
15 the patient's blood is a concentration of glucose therein.

20

25

30

### ABSTRACT

A method and system for measuring time variations of a response of a blood  
5 perfused fleshy medium to an external electromagnetic field is provided. The  
response of the medium to the external electromagnetic field can be a photo-  
acoustic signal, obtained in response to the exciting light, and/or impedance of the  
medium, in response to the applied *ac* electromagnetic field. Measurements of the  
time variations of the response of the medium are carried out when the condition of  
10 artificial kinetics is created and maintained over a certain time period by applying  
primary over-systolic pressure to a certain location at the medium with normal  
blood flow, so as to achieve a state of temporary blood flow cessation at the  
medium downstream of the certain location. When required, the control of the  
condition of the artificial kinetics can be further achieved by applying a  
15 perturbation of secondary pressure to the fleshy medium.

## DECLARATION FOR PATENT APPLICATION

Attorney Docket: 25815  
Page 1 of 2

As a below-named inventor(s), I/we hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) is/are as stated below next to my/our name(s).

I/We believe I/we am/are the original inventor, first and sole (if only one name is listed below) or the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed, and for which a patent is sought on the invention entitled:

METHOD AND SYSTEM FOR NON-INVASIVE DETERMINATION OF BLOOD-RELATED PARAMETERS

the specification of which: (check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_, as Serial No. \_\_\_\_\_,  
and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the patentability of this application as defined by 37 CFR ' 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. ' 119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications:

(Application No.) _____	(Country) _____	(Day/Month/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Application No.) _____	(Country) _____	(Day/Month/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Application No.) _____	(Country) _____	(Day/Month/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No

We hereby appoint Gary M. Nath, Reg. No. 26,965; Harold L. Novick, Reg. No. 26,011; Todd L. Juneau, Reg. No. 40,669; Lee C. Heiman, Reg. No. 41,827; Jerald L. Meyer, Reg. No. 41,194; Joshua B. Goldberg, Reg. No. 44,126; Marvin C. Berkowitz, Reg. No. 47,421; Sheldon McGee, Reg. No. 50,454; Tanya E. Harkins, Reg. No. 52,993; Robert C. Ryan, Reg. No. 29,343; and Derek Richmond, Reg. No. 45,771; as my attorneys to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct Telephone Calls to:

Gary M. Nath  
(202) 775-8383

Send Correspondence to:  
NATH & ASSOCIATES, PLLC  
Sixth Floor  
1030 15<sup>th</sup> Street, N.W.  
Washington, D.C. 20005 U.S.A.

We hereby claim the benefit under 35 U.S.C. ' 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by 35 U.S.C. ' 112, first paragraph, I/we acknowledge the duty to disclose material information as defined in 37 CFR ' 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. Application Serial No.) \_\_\_\_\_ (U.S. Filing Date) \_\_\_\_\_ (Status--patented, pending, abandoned)

(U.S. Application Serial No.) \_\_\_\_\_ (U.S. Filing Date) \_\_\_\_\_ (Status--patented, pending, abandoned)

## DECLARATION FOR PATENT APPLICATION

Attorney Docket: 25815  
Page 2 of 2

I/we hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number(s) \_\_\_\_\_

Filing Date \_\_\_\_\_

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. ' 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Ilya FINE

Inventor's Signature \_\_\_\_\_ Date: \_\_\_\_\_

Residence: 59/6 Herzl Street, Rehovot 76540, ISRAELCountry of Citizenship: ISRAELPost Office Address: same as aboveFull name of second inventor: Alexander FINAROV

Inventor's Signature \_\_\_\_\_ Date: \_\_\_\_\_

Residence: 1/10 Kovshey Ha-Hermon, Rehovot 76555, ISRAELCountry of Citizenship: ISRAELPost Office Address: same as aboveFull name of third inventor: Iosef GANDELMAN

Inventor's Signature \_\_\_\_\_ Date: \_\_\_\_\_

Residence: 22/22 Hatzmout Street, Ashdod 77452, ISRAELCountry of Citizenship: ISRAELPost Office Address: same as aboveFull name of fourth inventor: Boris FIKHTE

Inventor's Signature \_\_\_\_\_ Date: \_\_\_\_\_

Residence: 17/6 Miller Avia, Rehovot 76284, ISRAELCountry of Citizenship: ISRAELPost Office Address: same as above

1/4




FIG. 1

2/4




FIG. 2




FIG. 3

3/4




FIG. 4




FIG. 5

4/4




FIG. 6



# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IL04/001015

International filing date: 04 November 2004 (04.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 10/702,044  
Filing date: 06 November 2003 (06.11.2003)

Date of receipt at the International Bureau: 05 January 2005 (05.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**